556-97-8Relevant articles and documents
Meta halogenation of 1,3-disubstituted arenes via iridium-catalyzed arene borylation
Murphy, Jaclyn M.,Liao, Xuebin,Hartwig, John F.
, p. 15434 - 15435 (2008/09/19)
We report the meta halogenation of 1,3-disubstituted arenes to form 3,5-disubstituted aryl bromides and chlorides by using iridium-catalyzed arene borylation chemistry. Iridium-catalyzed borylation of arenes with B2pin2, followed by reaction of the boronic ester with copper(II) bromide or chloride converts arylboronic esters to the corresponding aryl halides. A variety of arenes containing alkoxy, alkyl, halogen, nitrile, ester, amide, and pivaloyl and TIPS-protected alcohols were converted to the corresponding 3,5-disubstituted aryl bromides and chlorides in yields ranging from 46% to 85%. In addition, 2,6-disubstituted and 3-substituted pyridines were converted to the 4-halo and 5-halopyridines, respectively. The utility of this methodology was demonstrated by the formal conversion of nicotine to Altinicline in three steps with an overall yield of 61% using meta bromination of nicotine as the first step. Copyright
PROCESS FOR HALOGENATION OF BENZENE AND BENZENE DERIVATIVES
-
Page/Page column 23-24, (2008/06/13)
In a process of halogenation of benzene or benzene derivatives, di-substituted halobenzene derivatives having para-aromatic compounds or tri-substituted halobenzene derivatives having 1,2,4-substituted aromatic compounds are selectively produced. In halogenation of benzene or benzene derivatives, a fluorine-containing zeolite catalyst such as L-type zeolite, or a zeolite catalyst having the crystal size of at most 100 nm is used. The reaction is preferably effected in the presence of a solvent, and the solvent is preferably a halogenated compound.
Phosphosulfonate herbicides
-
, (2008/06/13)
This invention pertains to phosphosulfonates, having the general formula STR1 wherein Y is phenyl, naphthyl, benzyl, a (C5 -C8)cycloalkyl, a 5-membered heteroaromatic ring, a 6-membered heteraromatic ring, a fused 5,6-membered heteroaromatic ring, or a fused 6,6-membered heteroaromatic ring; and X is oxygen or sulfur; and R1 and R2 are each independently selected from substituted or unsubstituted alkyl, alkoxy, alkylthio, alkenyloxy, alkynyloxy, haloalkoxy, cyanoalkoxy, alkoxyalkoxy, cycloalkyloxy, cycloalkylalkoxy, alkylideneiminooxy, chloro, amino, phenyl or phenoxy; or R1 and R2 are both alkoxy, taken together with the phosphorus atom to form a 6-membered oxygen-containing ring; compositions containing these compounds and their use as herbicides.
The Triazene Moiety as a Protecting Group for Aromatic Amines
Gross, Margaret L.,Blank, David H.,Welch, Willard M.
, p. 2104 - 2109 (2007/10/02)
Reaction of (2-), (3-), and (4-bromophenyl)-3,3-(1,4-butanediyl)triazenes (derived from the corresponding 2-, 3-, and 4-bromoanilines) with sec- or tert-butyllithiums gave the corresponding (triazenylaryl)lithiums; these intermediates reacted with a variety of electrophiles to give substituted aryl triazenes.These products could be converted to substituted anilines by reduction or to novel substituted aromatics by a modified Sandmeyer reaction.
Treatment of migraine with substituted tropyl benzoate derivatives
-
, (2008/06/13)
Migraine is treated with a tropyl benzoate derivative of the following general formula: STR1 wherein: R1 represents C1 -C4 alkyl, C1 -C4 alkoxy or halogen; R2 represents hydrogen, C1 -C4 alkyl, C1 -C4 alkoxy or halogen; and R3 represents hydrogen, C1 -C4 alkyl, C1 -C4 alkoxy or halogen, provided that R3 is hydrogen when R2 is hydrogen, or a pharmaceutically acceptable salt thereof. Additionally, some novel tropyl benzoate derivatives are disclosed.
Treatment of migraine with substituted tropyl benzoate derivatives
-
, (2008/06/13)
Migraine is treated with a tropyl benzoate derivative of the following general formula: STR1 wherein: R1 represents C1 -C4 alkyl, C1 -C4 alkoxy or halogen; R2 represents hydrogen, C1 -C4 alkyl, C1 -C4 alkoxy or halogen; and R3 represents hydrogen, C1 -C4 alkyl, C1 -C4 alkoxy or halogen, provided that R3 is hydrogen when R2 is hydrogen, or a pharmaceutically acceptable salt thereof. Additionally, some novel tropyl benzoate derivatives are disclosed.
